Want to see IL:NVLG full AI Analyst Report?
Top Page
Novolog
(TASE:NVLG)
Select Model
Select Model
Rating:58Neutral
Price Target:
91.00
▲(18.95% Upside)
Action:Reiterated
Date:10/08/26
The score is primarily driven by solid financial momentum (strong TTM revenue growth and a return to positive cash generation) but is held back by weakened profitability (margin compression and slightly negative TTM earnings). Technicals are mixed with a weak longer-term trend versus the 200 DMA, and valuation is constrained by a negative P/E despite a supportive dividend yield.
Positive Factors
Strong TTM revenue growth
The 56.4% TTM revenue increase indicates stronger recent sales activity and expanding business volume. If maintained, this growth can improve operating leverage, support reinvestment, and strengthen Novolog’s position in medical distribution over the coming quarters.
Negative Factors
Profitability deterioration
The move to slightly negative net income, alongside compressed gross and operating margins, shows that stronger sales are not currently translating into durable earnings. Thin profitability leaves less room to absorb cost pressure and may constrain reinvestment capacity.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong TTM revenue growth
The 56.4% TTM revenue increase indicates stronger recent sales activity and expanding business volume. If maintained, this growth can improve operating leverage, support reinvestment, and strengthen Novolog’s position in medical distribution over the coming quarters.
Read all positive factors
Novolog (NVLG) vs. iShares MSCI Israel ETF (EIS)
Market Cap
₪428.11M
Dividend Yield4.65%
Average Volume (3M)709.39K
Price to Earnings (P/E)―
Beta (1Y)0.75
Revenue Growth-13.76%
EPS Growth-103.31%
CountryIL
Employees916
SectorGeneral
Sector StrengthN/A
IndustryMedical - Distribution
Share Statistics
EPS (TTM)N/A
Shares Outstanding510,874,760
10 Day Avg. Volume667,441
30 Day Avg. Volume709,395
Financial Highlights & Ratios
PEG Ratio-1.73
Price to Book (P/B)1.80
Price to Sales (P/S)0.36
P/FCF Ratio-18.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Novolog Business Overview & Revenue Model
Company Description
Novolog (Pharm-Up 1966) Ltd provides healthcare services in Israel. The company operates through three divisions: Logistics, Healthcare Services, and Digital. The Logistics division engages in the import and distribution of pharmaceuticals and med...
Novolog Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
63
Positive
Cash Flow
60
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.81B | 1.81B | 2.02B | 1.64B | 1.51B | 1.26B |
| Gross Profit | 137.75M | 124.09M | 180.78M | 173.76M | 176.15M | 148.96M |
| EBITDA | 105.05M | 100.75M | 149.39M | 130.14M | 138.53M | 115.92M |
| Net Income | -674.00K | 4.12M | 39.54M | -42.00M | 47.51M | 42.32M |
Balance Sheet | ||||||
| Total Assets | 2.71B | 2.15B | 3.04B | 2.79B | 2.43B | 2.29B |
| Cash, Cash Equivalents and Short-Term Investments | 204.46M | 121.77M | 247.60M | 232.94M | 172.81M | 238.71M |
| Total Debt | 171.19M | 183.20M | 198.47M | 215.18M | 212.77M | 166.81M |
| Total Liabilities | 2.35B | 1.78B | 2.65B | 2.39B | 1.97B | 1.86B |
| Stockholders Equity | 350.91M | 356.85M | 368.38M | 371.08M | 436.00M | 424.37M |
Cash Flow | ||||||
| Free Cash Flow | 71.82M | -34.22M | 99.78M | 129.06M | 63.16M | 52.75M |
| Operating Cash Flow | 70.18M | -16.50M | 158.52M | 200.01M | 132.65M | 83.39M |
| Investing Cash Flow | -40.34M | -61.92M | -50.55M | -72.60M | -124.95M | -69.07M |
| Financing Cash Flow | -48.86M | -46.02M | -94.59M | -67.71M | -72.96M | 47.49M |
Novolog Technical Analysis
Neutral
76.50
Price Trends
80.29
Positive
78.21
Positive
93.95
Negative
Market Momentum
1.41
Positive
51.90
Neutral
25.58
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:NVLG, the sentiment is Neutral. The current price of 76.5 is below the 20-day moving average (MA) of 84.77, below the 50-day MA of 80.29, and below the 200-day MA of 93.95, indicating a neutral trend. The MACD of 1.41 indicates Positive momentum. The RSI at 51.90 is Neutral, neither overbought nor oversold. The STOCH value of 25.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IL:NVLG.
Novolog Peers Comparison
UnderperformOutperform
Sector (55)
IL:NVLG
Novolog
84.20
-42.16
-33.36%
IL:BONS
Bonus Biogroup
17.70
-3.80
-17.67%
IL:ILX
Ilex Medical
4,782.00
-1,485.05
-23.70%
IL:GEFR
Cannomed
76.40
-7.60
-9.05%
IL:MDPR
Medipower 0.1$
490.90
-195.54
-28.49%
IL:EPIT
Epitomee Med
336.30
-409.30
-54.90%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.